ALRT solves the largest problem in diabetes management (Clinical Inertia- failure to advance therapy on a timely basis) with unique and revolutionary features such as patent pending predictive A1C, FDA cleared insulin dose adjustments, non-insulin therapy advancements, direct meter uploads, data processing, remote care, and more.
ALR Technologies Announces Completion of Pivotal Non-Inferiority Study on the GluCurve Pet CGM
ALR Technologies Inc., the diabetes management company, today announced successful results from the conclusion of the non-inferiority study conducted on the GluCurve Pet CGM which was previously announced on February 10, 2022 and February 28, 2022.
ALR Technologies Announces Successful Preliminary Results for the GluCurve Pet CGM Non-Inferiority Study
ALR Technologies Inc., the diabetes management company, today announced preliminary results from the Non-Inferiority Study currently being conducted on the GluCurve Pet CGM (GluCurve)
ALR Technologies is a data management company that developed the ALRT Diabetes Solution, a comprehensive approach to diabetes care that includes: an FDA-cleared and HIPAA compliant diabetes management system that collects data directly from blood glucose meters and continuous glucose monitoring devices; a patent pending Predictive A1C algorithm to track treatment success between lab reports and an FDA-cleared Insulin Dosing Adjustment program. Currently, the Company is focused on diabetes and will expand its services to cover other chronic diseases anchored on verifiable data.
In addition, the animal health division has identified an unmet need in diabetes care and has developed a solution to assist veterinarians in determining the effectiveness of insulin and helping to identify the appropriate dose and frequency of administration for companion animals. Thus, delivering the same optimization of diabetic drug therapies to pets as to humans.